The second phase of clinical trials for the corona vaccine, developed by Oxford University, began in India on Tuesday. The Serum Institute of India (SII) in Pune will conduct trials on the Covishield vaccine. Bharathi Vidyapeeth Medical College, Hospital, Pune is the venue for these tests to ascertain the safety of the vaccine inoculation and its immunity.
It is known that SII has partnered with the British company Astrogenica to produce the Covid-19 vaccine developed by Oxford.
We are going to make the world leading Covid-19 vaccine available to our countrymen. “We will make our country ‘self-sufficient’,” said Prakash Kumar Singh, a senior official at SII. SII sources state that the vaccine will be administered to 1,600 people over the age of 18 in 17 locations across the country. It is reported that on August 3, the Drugs Controller General of India granted permission to SII to conduct second and third phase experiments on humans.
Citing Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs, SII, the reports suggest that the company has received all the permits from the Central Drugs Standard Control Organisation (CDSCO) and trials are set to commence from August 25. Singh said that the manufacturing of vaccines in India is in accordance with the company’s norms and India’s mission for an ‘AatmaNirbhar’ country